Rothschild Investment LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $444K | Buy |
7,865
+3,353
| +74% | +$196K | 0.02% | 428 |
|
|
2025
Q4 | $268K | Sell |
4,512
-8,695
| -66% | -$473K | 0.01% | 528 |
|
|
2025
Q3 | $715K | Buy |
13,207
+3,833
| +41% | +$219K | 0.04% | 285 |
|
|
2025
Q2 | $515K | Sell |
9,374
-251
| -3% | -$14.8K | 0.03% | 333 |
|
|
2025
Q1 | $680K | Sell |
9,625
-105
| -1% | -$7.06K | 0.05% | 282 |
|
|
2024
Q4 | $640K | Sell |
9,730
-1,124
| -10% | -$75.3K | 0.04% | 299 |
|
|
2024
Q3 | $763K | Sell |
10,854
-150
| -1% | -$12.5K | 0.05% | 274 |
|
|
2024
Q2 | $906K | Sell |
11,004
-3,210
| -23% | -$267K | 0.06% | 239 |
|
|
2024
Q1 | $1.24M | Buy |
14,214
+210
| +1% | +$18.8K | 0.09% | 198 |
|
|
2023
Q4 | $1.35M | Sell |
14,004
-300
| -2% | -$26.5K | 0.11% | 155 |
|
|
2023
Q3 | $1.27M | Sell |
14,304
-700
| -5% | -$62.3K | 0.11% | 177 |
|
|
2023
Q2 | $1.3M | Sell |
15,004
-151
| -1% | -$14.2K | 0.11% | 183 |
|
|
2023
Q1 | $1.47M | Sell |
15,155
-99
| -0.6% | -$10.3K | 0.13% | 158 |
|
|
2022
Q4 | $1.58M | Sell |
15,254
-406
| -3% | -$38.1K | 0.15% | 148 |
|
|
2022
Q3 | $1.33M | Buy |
15,660
+56
| +0.4% | +$4.99K | 0.13% | 163 |
|
|
2022
Q2 | $1.29M | Buy |
15,604
+1,050
| +7% | +$83.6K | 0.12% | 177 |
|
|
2022
Q1 | $1.12M | Hold |
14,554
| – | – | 0.09% | 212 |
|
|
2021
Q4 | $1.29M | Buy |
14,554
+481
| +3% | +$39.7K | 0.1% | 192 |
|
|
2021
Q3 | $1.09M | Sell |
14,073
-300
| -2% | -$23.7K | 0.09% | 211 |
|
|
2021
Q2 | $1.2M | Sell |
14,373
-425
| -3% | -$33.7K | 0.1% | 199 |
|
|
2021
Q1 | $1.12M | Buy |
14,798
+200
| +1% | +$16.3K | 0.1% | 205 |
|
|
2020
Q4 | $1.28M | Buy |
14,598
+162
| +1% | +$12.8K | 0.12% | 167 |
|
|
2020
Q3 | $1.1M | Sell |
14,436
-2,880
| -17% | -$291K | 0.12% | 163 |
|
|
2020
Q2 | $2.14M | Sell |
17,316
-993
| -5% | -$98.7K | 0.26% | 99 |
|
|
2020
Q1 | $1.55M | Sell |
18,309
-410
| -2% | -$35.3K | 0.2% | 119 |
|
|
2019
Q4 | $1.58M | Buy |
18,719
+1,500
| +9% | +$113K | 0.16% | 145 |
|
|
2019
Q3 | $1.16M | Sell |
17,219
-400
| -2% | -$30.8K | 0.14% | 149 |
|
|
2019
Q2 | $1.51M | Buy |
17,619
+4,585
| +35% | +$392K | 0.18% | 129 |
|
|
2019
Q1 | $1.16M | Buy |
13,034
+100
| +0.8% | +$9.27K | 0.14% | 158 |
|
|
2018
Q4 | $1.1M | Sell |
12,934
-100
| -0.8% | -$9.51K | 0.15% | 136 |
|
|
2018
Q3 | $1.26M | Sell |
13,034
-665
| -5% | -$66.4K | 0.15% | 144 |
|
|
2018
Q2 | $1.29M | Hold |
13,699
| – | – | 0.16% | 140 |
|
|
2018
Q1 | $1.11M | Buy |
13,699
+6,330
| +86% | +$543K | 0.14% | 154 |
|
|
2017
Q4 | $657K | Buy |
+7,369
| New | +$641K | 0.07% | 242 |
|
Other funds holding BMRN
VCM
VPM
Rothschild Investment LLC's BMRN Position: Q1 2026 in Review
Rothschild Investment LLC increased its BioMarin Pharmaceuticals (BMRN) stake by 74% in Q1 2026, buying an estimated $196K and bringing the position to 7,865 shares worth $444K. The position accounts for 0.02% of the portfolio, ranked #428.
Rothschild Investment LLC first reported a position in BMRN in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.14M in Q2 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Rothschild Investment LLC held 7,865 shares of BioMarin Pharmaceuticals worth $444K as of Q1 2026.
- Rothschild Investment LLC bought 3,353 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $196K.
- BioMarin Pharmaceuticals made up 0.02% of Rothschild Investment LLC's portfolio in Q1 2026, its #428 holding.
- Rothschild Investment LLC first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Rothschild Investment LLC's BioMarin Pharmaceuticals position peaked at $2.14M in Q2 2020.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.